Scholars Central

Conference abstractPublished 18 Mar 2021

Health economics and patient outcomes of non-myeloablative hematopoietic stem cell transplantation (HSCT) versus disease-modifying therap (DMT) for relapsing remitting multiple sclerosis in the United States of America

Authors: Richard K Burt

Journal of Biomedical Science & Applications

Volume 5 · Issue 2 · Pages 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

To estimate differences in treatment costs and health outcomes between non-myeloablative hematopoietic stem cell transplantation (HSCT) and disease-modifying therapies (DMTs) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Importance Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS). Objective To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease progression. Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS).

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Biomedical Science & Applications.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Biomedical Science & Applications
  • SubjectGenetics & Molecular Biology
  • SubjectSurgery
  • SubjectBusiness & Management
  • BylineArticles whose byline prints “Richard K Burt”